Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer

International Journal of Experimental Pathology

Volumn 91, Issue 4, 2010, Pages 324-334

  García, María Fernanda ^a   González Reyes, Salomé ^a,b   González, Luis Ovidio ^a,b   Junquera, Sara ^a   Berdize, Nana ^c   Del Casar, José Manuel ^a,b   Medina, María ^b,d   Vizoso, Francisco José ^a,b  

^a HOSPITAL DE JOVE   (Spain)

^b DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^c HOSPITAL DE CABUEÑES   (Spain)

^d UNIVERSITY OF OVIEDO   (Spain)

Author keywords

axillary lymph node; invasive front; leucocytes; matrix metalloproteinase; tissue inhibitors of metalloproteases; tumour heterogeneity

Indexed keywords

ANTINEOPLASTIC AGENT; COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE 14; STROMELYSIN 3; TAMOXIFEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER LOCALIZATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CLUSTER ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASES, SECRETED; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; STROMAL CELLS; SURVIVAL ANALYSIS; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASES; TREATMENT OUTCOME;

EID: 77955063687     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/j.1365-2613.2010.00709.x     Document Type: Article

References (58)

1. Abdel-Ghany M., Cheng H.C., Elble R.C., Pauli B.U. (2001) The breast cancer beta 4 integrin and endothelial human CLCA2 mediate lung metastasis. J. Biol. Chem. 276, 25438 25446.
2. Agarwal B., Saxena R., Morimiya A., Mehrotra S., Badve S. (2005) Lymphangiogenesis does not occur in breast cancer. Am. J. Surg. Pathol. 29, 1449 1455.
3. Ahonen M., Baker A.H., Kahari V.M. (1998) Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res. 58, 2310 2315.
4. Andersen J. Poulsen H.S. (1988) Relationship between estrogen receptor status in the primary tumour and its regional and distant metastases. An immunohistochemical study in human breast cancer. Acta Oncol. 27, 761 765.
5. Baker A.H., George S.J., Zaltsman A.B., Murphy G., Newby A.C. (1999) Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br. J. Cancer 79, 1347 1355.
6. Behrens P., Rothe M., Wellmann A., Krischler J., Wernert N. (2001) The Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer. J. Pathol. 194, 43 50.
7. Cady B. (2007) Regional lymph node metastases; a singular manifestation of the process of clinical metastases in cancer: contemporary animal research and clinical reports suggest unifying concepts. Ann. Surg. Oncol. 14, 1790 1800.
8. Chang D.B., Yang P.C., Chang K.J., Luh K.T., Kuo S.H. (1993) Comparison of DNA stemline and cell kinetics between primary breast cancer and its lymph node metastasis. Anal. Quant. Cytol. Histol. 15, 32 38.
9. Chantrain C.F., Shimada H., Jodele S. et al. (2004) Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer. Res. 64, 1675 1686.
10. Cornelius L.A., Nehring L.C., Harding E. et al. (1998) Matrix metalloproteinases generate angiostatin: effects on neovascularization. J. Immunol. 161, 6845 6852.
11. Daidone M.G., Silvestrini R., Valentinis B. et al. (1990) Proliferative activity of primary breast cancer and of synchronous lymph node metastases evaluated by [3H]-thymidine labelling index. Cell. Tissue. Kinet. 23, 401 408.
12. Davies G., Jiang W.G., Mason M.D. (2001) Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion. Clin. Cancer Res. 7, 3289 3297.
13. Del Casar J.M., Gonzalez L.O., Alvarez E. et al. (2009) Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas. Breast. Cancer Res. Treat. 116, 39 52.
14. Demers M., Couillard J., Belanger S., St-Pierre Y. (2005) New roles for matrix metalloproteinases in metastasis. Crit. Rev. Immunol. 25, 493 523.
15. Duffy M.J., Maguire T.M., Hill A., McDermott E., O'Higgins N. (2000) Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast. Cancer Res. 2, 252 257.
16. Egeblad M. Werb Z. (2002) New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161 174.
17. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. (1998) Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA. 95, 14863 14868.
18. Feichter G.E., Kaufmann M., Muller A. et al. (1989) DNA index and cell cycle analysis of primary breast cancer and synchronous axillary lymph node metastases. Breast Cancer Res. Treat. 13, 17 22.
19. Ferreras M., Felbor U., Lenhard T., Olsen B.R., Delaisse J. (2000) Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 486, 247 251.
20. Fingleton B., Vargo-Gogola T., Crawford H.C., Matrisian L.M. (2001) Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 3, 459 468.
21. Gonzalez L.O., Pidal I., Junquera S. et al. (2007) Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br. J. Cancer 97, 957 963.
22. Goodson W.H. III., Ljung B.M., Moore D.H. II. et al. (1993) Tumor labeling indices of primary breast cancers and their regional lymph node metastases. Cancer 71, 3914 3919.
23. Irjala H., Alanen K., Grenman R. et al. (2003) Mannose receptor (MR) and common lymphatic endothelial and vascular endothelial receptor (CLEVER)-1 direct the binding of cancer cells to the lymph vessel endothelium. Cancer Res. 63, 4671 4676.
24. Jiang Y., Goldberg I.D., Shi Y.E. (2002) Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21, 2245 2252.
25. Jones J.L., Glynn P., Walker R.A. (1999) Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J. Pathol. 189, 161 168.
26. Kang Y., Siegel P.M., Shu W. et al. (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537 549.
27. Knauper V., Lopez-Otin C., Smith B., Knight G., Murphy G. (1996) Biochemical characterization of human collagenase-3. J. Biol. Chem. 271, 1544 1550.
28. Kotzsch M., Farthmann J., Meye A. et al. (2005) Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer. Eur. J. Cancer 41, 2760 2768.
29. Meller D., Li D.Q., Tseng S.C. (2000) Regulation of collagenase, stromelysin, and gelatinase B in human conjunctival and conjunctivochalasis fibroblasts by interleukin-1beta and tumor necrosis factor-alpha. Invest. Ophthalmol. Vis. Sci. 41, 2922 2929.
30. Minn A.J., Gupta G.P., Siegel P.M. et al. (2005) Genes that mediate breast cancer metastasis to lung. Nature 436, 518 524.
31. Moffett B.F., Baban D., Bao L., Tarin D. (1992) Fate of clonal lineages during neoplasia and metastasis studied with an incorporated genetic marker. Cancer Res. 52, 1737 1743.
32. Mori T., Morimoto T., Komaki K., Monden Y. (1991) Comparison of estrogen receptor and epidermal growth factor receptor content of primary and involved nodes in human breast cancer. Cancer 68, 532 537.
33. Nielsen B.S., Rank F., Lopez J.M. et al. (2001) Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. Cancer Res. 61, 7091 7100.
34. Nishizaki T., DeVries S., Chew K. et al. (1997) Genetic alterations in primary breast cancers and their metastases: direct comparison using modified comparative genomic hybridization. Genes Chromosomes Cancer 19, 267 272.
35. Noe V., Fingleton B., Jacobs K. et al. (2001) Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J. Cell. Sci. 114, 111 118.
36. Overall C.M. Lopez-Otin C. (2002) Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2, 657 672.
37. Ree A.H., Florenes V.A., Berg J.P. et al. (1997) High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin. Cancer Res. 3, 1623 1628.
38. Remacle A., McCarthy K., Noel A. et al. (2000) High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int. J. Cancer 89, 118 121.
39. Rifkin D.B., Mazzieri R., Munger J.S., Noguera I., Sung J. (1999) Proteolytic control of growth factor availability. Apmis 107, 80 85.
40. Sato T., Sakai T., Noguchi Y. et al. (2004) Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol. Oncol. 92, 47 56.
41. Schrohl A.S., Holten-Andersen M.N., Peters H.A. et al. (2004) Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin. Cancer Res. 10, 2289 2298.
42. Span P.N., Lindberg R.L., Manders P. et al. (2004) Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. J. Pathol. 202, 395 402.
43. Spurbeck W.W., Ng C.Y., Strom T.S., Vanin E.F., Davidoff A.M. (2002) Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. Blood 100, 3361 3368.
44. Stamenkovic I. (2000) Matrix metalloproteinases in tumor invasion and metastasis. Semin. Cancer Biol. 10, 415 433.
45. Sternlicht M.D. Werb Z. (2001) How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell. Dev. Biol. 17, 463 516.
46. Stetler-Stevenson W.G. (1999) Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J. Clin. Invest. 103, 1237 1241.
47. Storm F.K., Mahvi D.M., Gilchrist K.W. (1996) Heat shock protein 27 overexpression in breast cancer lymph node metastasis. Ann. Surg. Oncol. 3, 570 573.
48. Strongin A.Y., Collier I., Bannikov G. et al. (1995) Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. 270, 5331 5338.
49. Talvensaari-Mattila A. Turpeenniemi-Hujanen T. (2005) Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma. Cancer Lett. 217, 237 242. (Pubitemid 40023123)
50. Talvensaari-Mattila A., Paakko P., Turpeenniemi-Hujanen T. (2003) Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br. J. Cancer 89, 1270 1275. (Pubitemid 37363416)
51. Tommasi S., Giannella C., Paradiso A. et al. (1992) HER-2/neu gene in primary and local metastatic axillary lymph nodes in human breast tumors. Int. J. Biol. Markers 7, 107 113.
52. Umekita Y., Sagara Y., Yoshida H. (1998) Estrogen receptor mutations and changes in estrogen receptor and progesterone receptor protein expression in metastatic or recurrent breast cancer. Jpn. J. Cancer Res. 89, 27 32.
53. van Agthoven T., Timmermans M., Dorssers L.C., Henzen-Logmans S.C. (1995) Expression of estrogen, progesterone and epidermal growth factor receptors in primary and metastatic breast cancer. Int. J. Cancer 63, 790 793.
54. Vizoso F.J., Gonzalez L.O., Corte M.D. et al. (2007) Study of matrix metalloproteinases and their inhibitors in breast cancer. Br. J. Cancer 96, 903 911.
55. Vleugel M.M., Bos R., van der Groep P. et al. (2004) Lack of lymphangiogenesis during breast carcinogenesis. J. Clin. Pathol. 57, 746 751.
56. Wang F., Reierstad S., Fishman D.A. (2006) Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation. Cancer Lett. 236, 292 301.
57. Wurtz S.O., Schrohl A.S., Sorensen N.M. et al. (2005) Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr. Relat. Cancer 12, 215 227.
58. Yu W.H., Woessner J.F. Jr., McNeish J.D., Stamenkovic I. (2002) CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes. Dev. 16, 307 323.